JP6051164B2 - 心肺バイパス用プライミング液 - Google Patents

心肺バイパス用プライミング液 Download PDF

Info

Publication number
JP6051164B2
JP6051164B2 JP2013541272A JP2013541272A JP6051164B2 JP 6051164 B2 JP6051164 B2 JP 6051164B2 JP 2013541272 A JP2013541272 A JP 2013541272A JP 2013541272 A JP2013541272 A JP 2013541272A JP 6051164 B2 JP6051164 B2 JP 6051164B2
Authority
JP
Japan
Prior art keywords
dextran
solution
colloid
blood
osmotic pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013541272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544265A (ja
JP2013544265A5 (cg-RX-API-DMAC10.html
Inventor
ステーン，スティグ
Original Assignee
エクスビボ パフュージョン アクチボラゲット
エクスビボ パフュージョン アクチボラゲット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクスビボ パフュージョン アクチボラゲット, エクスビボ パフュージョン アクチボラゲット filed Critical エクスビボ パフュージョン アクチボラゲット
Publication of JP2013544265A publication Critical patent/JP2013544265A/ja
Publication of JP2013544265A5 publication Critical patent/JP2013544265A5/ja
Application granted granted Critical
Publication of JP6051164B2 publication Critical patent/JP6051164B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
JP2013541272A 2010-11-30 2011-11-07 心肺バイパス用プライミング液 Active JP6051164B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1020300.8 2010-11-30
GBGB1020300.8A GB201020300D0 (en) 2010-11-30 2010-11-30 Product
PCT/EP2011/069524 WO2012072374A1 (en) 2010-11-30 2011-11-07 Priming solutions for cardiopulmonary bypass

Publications (3)

Publication Number Publication Date
JP2013544265A JP2013544265A (ja) 2013-12-12
JP2013544265A5 JP2013544265A5 (cg-RX-API-DMAC10.html) 2014-12-25
JP6051164B2 true JP6051164B2 (ja) 2016-12-27

Family

ID=43500877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541272A Active JP6051164B2 (ja) 2010-11-30 2011-11-07 心肺バイパス用プライミング液

Country Status (10)

Country Link
US (1) US8969323B2 (cg-RX-API-DMAC10.html)
EP (1) EP2646040B1 (cg-RX-API-DMAC10.html)
JP (1) JP6051164B2 (cg-RX-API-DMAC10.html)
CN (1) CN103228285B (cg-RX-API-DMAC10.html)
DK (1) DK2646040T3 (cg-RX-API-DMAC10.html)
ES (1) ES2575206T3 (cg-RX-API-DMAC10.html)
GB (1) GB201020300D0 (cg-RX-API-DMAC10.html)
PL (1) PL2646040T3 (cg-RX-API-DMAC10.html)
RU (1) RU2013127665A (cg-RX-API-DMAC10.html)
WO (1) WO2012072374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018133921A1 (en) 2017-01-17 2018-07-26 Xvivo Perfusion Ab Organ preservation and/or perfusion solutions
US11707600B2 (en) * 2020-11-18 2023-07-25 CardioDriven, Inc. Level set calibration and assurance for pulmonary artery pressure catheterization
CN117481629B (zh) * 2023-12-29 2024-03-26 成都水木医疗科技有限公司 一种多功能胶体渗透压仪及其测定方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1594697A (en) 1977-04-19 1981-08-05 Pharmacia Ab Oligosaccharide compositions for parenteral use
SE8900586L (sv) * 1989-02-21 1990-08-22 Pharmacia Ab Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader
PT701455E (pt) 1993-06-04 2001-09-27 Biotime Inc Solucao semelhante a plasma
SE505499C2 (sv) * 1995-12-15 1997-09-08 Stiftelsen Facthor Förvaringslösning för organ och vävnad eller delar därav från människor och djur innehållande kalcium och nitroglycerin, användning därav samt förfarande för förvaring därmed
US6794124B2 (en) * 1995-12-15 2004-09-21 Stiftelsen Facthor Preservation solution
US5902800A (en) 1998-03-27 1999-05-11 Glenpharma Dextran formulations and method for treatment of inflammatory joint disorders

Also Published As

Publication number Publication date
PL2646040T3 (pl) 2017-04-28
RU2013127665A (ru) 2015-01-10
CN103228285B (zh) 2016-06-01
WO2012072374A1 (en) 2012-06-07
ES2575206T3 (es) 2016-06-27
EP2646040A1 (en) 2013-10-09
JP2013544265A (ja) 2013-12-12
EP2646040B1 (en) 2016-03-23
GB201020300D0 (en) 2011-01-12
US8969323B2 (en) 2015-03-03
US20130316977A1 (en) 2013-11-28
DK2646040T3 (en) 2016-06-13
CN103228285A (zh) 2013-07-31

Similar Documents

Publication Publication Date Title
Checchia et al. Nitric oxide delivery during cardiopulmonary bypass reduces postoperative morbidity in children—a randomized trial
Barcelona et al. Intraoperative pediatric blood transfusion therapy: a review of common issues. Part II: transfusion therapy, special considerations, and reduction of allogenic blood transfusions.
JP5823530B2 (ja) 危険にさらされた組織のオキシジェネーション増進方法
JP2022500501A (ja) 血漿含有組成物
WO2016201081A1 (en) Composition and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
TWI554269B (zh) 用於治療自體消化之組成物
AU2016431615A1 (en) Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
Hasija et al. Bivalirudin anticoagulation in neonates and infants undergoing cardiac surgery
JP2013544265A (ja) 心肺バイパス用プライミング液
Kasper et al. Failure of autologous fresh frozen plasma to reduce blood loss and transfusion requirements in coronary artery bypass surgery
Friedman et al. Hemodynamic effects of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients
Gertler et al. Cardiopulmonary bypass
RU2409395C1 (ru) Способ восполнения массивной периоперационной кровопотери
Abdelazim et al. Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized controlled study
Davis et al. Use of thromboelastograph and factor VII for the treatment of postoperative bleeding in a pediatric patient on ECMO after cardiac surgery
Padalino et al. Modified ultrafiltration in pediatric heart surgery
Zarro et al. Albumin in the pump prime: its effect on postoperative weight gain
Pantaleon Fluid therapy in equine patients: small-volume fluid resuscitation
Vercueil et al. Resuscitation fluids in trauma, part II: which fluid should I give?
BRANCH PROSPECTIVE RANDOMISED COMPARATIVE STUDY OF EFFICACY OF COMBINATION OF TRANEXAMIC ACID AND ETHAMSYLATE BY ORAL AND INTRAVENOUS ROUTES IN RELATION TO CONTROL OF BLEEDING IN CARDIAC SURGERIES.
Draaisma Stepwise Improvement of Cardiopulmonary Bypass for Neonates and Infants
Mueller et al. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy
Kaye 23 FLUID MANAGEMENT
Bishnoi et al. A comparison of crystalloid versus colloid used as priming solution for cardiopulmonary bypass during open heart surgery in adult patients
CASE RUPTURED ABDOMINAL AORTIC ANEURYSM-OPEN ABDOMINAL AORTIC ANEURYSM REVISITED

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161128

R150 Certificate of patent or registration of utility model

Ref document number: 6051164

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250